Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis-Reference-Cited by-同舟云学术

Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis

Published:2017-11-16 Issue:6 Volume:177 Page:1537-1551
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Papp K.A.¹²,Bachelez H.³,Blauvelt A.⁴,Winthrop K.L.⁵,Romiti R.⁶,Ohtsuki M.⁷,Acharya N.⁸,Braun D.K.⁸,Mallbris L.⁸,Zhao F.⁸,Xu W.⁸,Walls C.D.⁸^ORCID,Strober B.²⁹

Affiliation:

1. K. Papp Clinical Research; Waterloo ON Canada

2. Probity Medical Research; Waterloo ON Canada

3. Service de Dermatologie; AP-HP Hôpital Saint Louis; Sorbonne Paris Cité Université Paris Diderot; Paris France

4. Oregon Medical Research Center; Portland OR U.S.A.

5. Oregon Health and Science University; Portland OR U.S.A.

6. Departament of Dermatology; Hospital das Clínicas da Universidade de São Paulo; São Paulo Brazil

7. Department of Dermatology; Jichi Medical University; Shimotsuke Japan

8. Eli Lilly and Company; Indianapolis IN U.S.A.

9. Department of Dermatology; University of Connecticut Health Center; Farmington CT U.S.A.

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.15723/fullpdf

Reference36 articles.

1. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1);Leonardi;Lancet,2008

2. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction;Papp;Br J Dermatol,2005

3. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial;Menter;J Am Acad Dermatol,2008

4. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2);Papp;Lancet,2008

5. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial;Reich;Lancet,2005

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies;Expert Opinion on Drug Safety;2024-09-12

2. Evaluation of serial QuantiFERON‐TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti‐IL‐17 treatment (secukinumab and ixekizumab): Real‐world data from a tuberculosis‐endemic country;Australasian Journal of Dermatology;2024-07

3. Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2);Journal of the European Academy of Dermatology and Venereology;2024-03-07

4. Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA;Modern Rheumatology Journal;2024-02-17

5. Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled data from up to three years of treatment in randomized phase 3 trials;British Journal of Dermatology;2023-11-10